HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Palmedo, H. Articles by Biersack, H.-J. Search for Related Content PubMed PubMed Citation Articles by Palmedo, H. Articles by Biersack, H.-J.

Painful Multifocal Arthritis: Therapy with Rhenium 186 Hydroxyethylidenedi-phosphonate (¹⁸⁶Re HEDP) after Failed Treatment with Medication—Initial Results of a Prospective Study¹

¹ From the Departments of Nuclear Medicine (H.P., M.B., J.R., C.M., H.J.B.) and Internal Medicine (J.K.R., K.S.), University of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany. Received December 6, 2000; revision requested January 18, 2001; revision received March 12; accepted March 22. Address correspondence to H.P. (e-mail: palmedo@mailer.meb.uni-bonn.de).

Eight patients (77 joints) with polyarthritis were treated systemically with 570 MBq (15.4 mCi) of rhenium 186 (¹⁸⁶Re) hydroxyethylidenediphosphonate (HEDP). Pain and disease activity were assessed monthly. In six (75%) of eight patients, a single injection of ¹⁸⁶Re HEDP led to an improvement in disease activity. Systemic low-dose treatment with ¹⁸⁶Re HEDP can reduce pain and disease activity in patients with polyarthritis.

Index terms: Arthritis, psoriatic, 30.72, 40.72 • Arthritis, rheumatoid, 30.71, 40.71 • Lupus erythematosus, 30.612, 40.612 • Radionuclides, therapeutic, 30.1269, 40.1269 • Rhenium, radioactive • Therapeutic radiology, 30.1269, 40.1269